The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating biomarkers of sorafenib efficacy in advanced HCC.
Leonidas Chelis
No relevant relationships to disclose
Kostantinos Anagnostopoulos
No relevant relationships to disclose
Grigorios Trypsianis
No relevant relationships to disclose
Eleni Kyrillos Hamalidou
No relevant relationships to disclose
Nikolaos Xenidis
No relevant relationships to disclose
Kiriakos Amarantidis
No relevant relationships to disclose
Savas Deftereos
No relevant relationships to disclose
Dimitra Pitsiava
No relevant relationships to disclose
Prodromos Michailidis
No relevant relationships to disclose
Evagelos Christakidis
No relevant relationships to disclose
Dimitrios Michailidis
No relevant relationships to disclose
Dimitrios Matthaios
No relevant relationships to disclose
Filio Koukaki
No relevant relationships to disclose
Alexandros H. Kortsaris
No relevant relationships to disclose
Stylianos Kakolyris
No relevant relationships to disclose